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Chapter I - Introduction 
One of the many unique features of Wave III of the Add Health Study was the collection 
of biological samples.  These biological samples permitted the identification of 
individuals with sexually transmitted infections [STI] (including HIV), and genotype 
ascertainment for pairs of full-siblings or twins who resided in the same households.  The 
STI testing allows for analyses of individual, household, family, and environmental risk 
factors for laboratory-confirmed sexually transmitted infections (versus self-report), and 
the genetic sample facilitates analyses that differentiate between parental, social, and 
genetic influence, as well as the extent to which genetic differences in neurotransmitter 
function are associated with a wide range of behaviors. 
The inclusion of these biomarker data requires special considerations in the analysis of 
Wave III Add Health data.  Thus, the purpose of this monograph is to outline relevant 
procedures, design, and sampling schemes used in the collection of biomarker data, and 
to serve as a user’s guide for its analysis and interpretation.  The monograph is intended 
to supplement existing descriptions of the Add Health study, rather than to replace them.  
Therefore, please refer to the web pages describing the Add Health Study design for more 
extensive detail on the study (www.cpc.unc.edu/addhealth) and the sampling weights 
necessary to work with the data (www.cpc.unc.edu/addhealth/codebooks/wave3). 
Issues that require special consideration include sample design (e.g., who was selected 
for each type of biomarker test), specimen collection, laboratory methods, and laboratory 
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test performance.  Each of these themes is described in separate chapters to this 
monograph, but should be viewed as complementary to each other.   
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Chapter II – Eligibility for Biomarker Samples 
Add Health Wave III data collection was designed to collect oral mucosal transudate 
(OMT) samples for HIV testing and urine samples for STI testing from all original Add 
Health respondents (n=20,745) who consented to provide these specimens.  Original 
respondents who were full siblings or twins (n=3787) were also asked to provide a saliva 
sample for DNA analysis.  Biological samples for HIV and STI testing were also 
collected from a special sample of recruited partners who consented to provide these 
specimens.  The partner sample at Wave III was designed to include partnerships 
representing the full spectrum of relationship intimacy and commitment.  The total 
sample was expected to be 1,500 partners, consisting of approximately one third married, 
one third cohabiting and one third dating partners. 
 
The partner interview was identical to the main respondent interview with the exception 
of questionnaire sections that used preloaded information from earlier wave data.  All 
Add Health respondents at Wave III were 18 years old or older at the time of data 
collection. 
 
Interviews were conducted nationwide, including Alaska and Hawaii.  Respondents who 
were overseas for the duration of the field work or who were in the Armed Forces and 
deployed overseas for the duration of the field work, were not eligible for a Wave III 
interview.  Interviews were conducted mostly in-home, but some interviews were 
conducted in school settings, work places, and other public places.  
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DNA Sample 
Original respondents who were identified to be full siblings or twins at earlier waves 
(3,787) were asked to provide a saliva sample for DNA analysis.  However, the recruited 
partners of these respondents were not asked to provide a DNA sample.  
 
HPV/Mycoplasma genitalium Sample 
The University of Washington (UW) requested 4,200 urine specimens from original 
female Add Health respondents.  In order to meet this quota, 7,000 original female Add 
Health respondents were randomly flagged for potential recruitment into this sample. The 
UW also requested 1,000 urine specimens from original male Add Health respondents. In 
order to meet this quota, 2,000 original male Add Health respondents were randomly 
flagged for potential recruitment into this sample.  Frozen aliquots of urine samples were 
shipped to the UW on dry ice and processed in the HPV and M. genitalium laboratories 
respectively. 
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Introduction 
The Add Health Wave III survey was a massive data collection endeavor that spanned the 
continental United States, Hawaii, and Alaska.  Between August 2001 and April 2002, a 
total of 15,197 original Add Health respondents and 1,507 of their married, cohabiting, or 
dating partners were interviewed in their homes or another location of their choice by a 
staff of 422 interviewers.  While it was anticipated that most interviews would be 
collected in in-home settings, to the extent that permission was obtained by local 
authorities and prison officials, and confidentiality of the interview could be assured, 
respondents and partners were interviewed and provided biological specimens in military 
bases, penitentiary facilities, and other institutions.  All Wave III respondents 18 years of 
age or older were asked to provide a urine specimen for Chlamydia trachomatis (CT), 
Neisseria gonorrhoeae (GC), and other experimental STI testing, and an oral mucosal 
transudate (OMT) specimen for Human Immunodeficiency Virus Type-1 (HIV-1) testing.  
 9 
This section summarizes field, transportation, and notification procedures related to these 
biospecimens. 
 
Informed Consent 
Wave III used a multiple-step consent process. Before the start of the interview, the 
interviewer described the Wave III interview and obtained consent for participation. 
During this process, respondents were informed that they would be asked to provide urine 
and OMT specimens at the end of the interview and, at the time they were asked to 
provide these specimens, they would be asked to sign additional consent forms. 
Completion of the interview was not linked with a requirement to provide biospecimens. 
At the end of the interview and in the following order, respondents were asked to 
independently consent to and provide a: 1) OMT Specimen for HIV Test; and 2) Urine 
Specimen for STI Tests.  
 
Interviewers provided respondents with the following information regarding the 
collection of HIV/STI biospecimens: 
 The OMT specimen would be tested for the presence of HIV antibodies.  
 The urine specimen would be tested for two curable STIs—chlamydia and gonorrhea. 
The urine samples would also be tested for other STIs but, because those tests have 
not yet been approved by the FDA as reliable using urine specimens, they would only 
be used for exploratory purposes and their results would not be made available. Add 
Health would not use urine samples to test for drug use. 
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 Add Health would not report the results for these tests to anyone else, and the security 
procedures make it impossible for others to know the respondent’s HIV or STI status. 
 If they provided the HIV OMT sample, they would receive an incentive of $10.  
 If they provided the urine specimen, they would receive an incentive of $10.  
 A toll-free telephone number to call four weeks after collection date to obtain results 
of the urine and HIV testing and to receive counseling. 
 A toll-free telephone number to obtain additional information about the study, as well 
as the number of the UNC IRB contact. 
 The toll-free 24-hour Centers for Disease Control and Prevention National STD and 
AIDS Hotline telephone number for general questions about HIV and STIs. 
 
Respondents were also provided verbal and written information about CT, GC, and HIV. 
Respondents were told that most who are infected do not experience symptoms, and 
provided with information on transmission, benefits of being tested and learning results, 
and the meaning of a positive and negative test result.  Respondents were told that 
persons notified of a positive test would be asked to go see a doctor or nurse. They also 
received information explaining that Add Health testing did not include testing for all 
STIs, and was not a substitute for regular medical care (including yearly Pap smears for 
sexually active women).  
 
Respondents received written sheets to be given to a health care provider if they had a 
positive test. This sheet provided information on interpretation of test results, 
recommended repeat serologic testing for positive HIV tests, and provided guidance and 
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references for management and treatment issues based on national guidelines [1].  Health 
care professionals were also referred to their local health department, infectious disease 
specialists in their region, and given the Centers for Disease Control and Prevention 
National STD and AIDS Hotline telephone number if they had questions. 
 
For respondents who were incarcerated at the time of the Add Health interview, 
biospecimen collection was only conducted if local IRB permission was obtained, prison 
administration agreed to all privacy and confidentiality requirements in the Add Health 
study protocol, the respondent was guaranteed unmonitored access to telephone calls to 
get his/her results, the respondent had access to adequate health services to re-test for, 
and/or treat STIs or HIV, and the respondent was given access to a private place to 
provide the urine sample.  Special informed consent forms as well as HIV and STI 
information sheets were designed for respondents who were incarcerated at the time of 
the interview.  There were no differences in incentive payments offered to incarcerated 
and non-incarcerated respondents. 
 
Field Collection  
OMT specimens were collected for HIV testing using the Orasure® Oral HIV-1 
Antibody Testing System. Respondents were instructed to place the pad of the collection 
device between the lower cheek and gum, to rub back and forth until moist, and to keep 
in place for a minimum of 2 minutes (timed by interviewer). The collection device was 
then placed in the vial supplied with the kit, and placed in a plastic bag. 
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Urine specimens were tested for CT and GC testing using Ligase Chain Reaction 
(LCR™) amplification technology in the Abbott LCx® Probe System. The assay 
required that 15-20 cc of first stream urine be collected in a plastic, preservative-free, 
sterile urine specimen collection cup from respondents who have not urinated within one 
hour prior to collection, and that the specimen be cooled immediately to 2-8ºC until 
processed.  Respondents received instructions about collection procedures from 
interviewers who had received extensive training (including training by Abbott 
Laboratory representatives), and samples were collected in a 30 cc cup with a black line 
marked at 15 cc. After securing the lid of the collection cup, specimens were placed in a 
plastic bag, and then inside of a styrofoam cooler with two ice packs.  If respondents 
asked to be excused to urinate before the end of the interview, consent and specimen 
collection occurred at that time to avoid situations where respondents would not be 
eligible to provide a specimen at the end of the interview because they had voided within 
the previous one-hour.  
 
A paper requisition was completed by the field interviewer and shipped along with the 
biospecimens.  A bar code label, identical to that used for labeling the urine and OraSure 
specimens, was affixed to the requisition.  The date and time of sample collection, and 
interviewer identification number were also recorded on the requisition. 
 
Transportation 
STI/HIV tests were packaged and mailed to the University of North Carolina at Chapel 
Hill.  Add Health packaging was approved by Federal Express as having met the 
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minimum packaging requirement for urine and saliva diagnostic specimens.  Packaging 
was also in compliance with OSHA standards for non-infectious, diagnostic specimens 
and biological requirements.  These requirements specify that packaging must include a 
primary receptacle, absorbent and cushioning material, a water-tight secondary container, 
other packaging (shipping container), and clinical specimens outer labels.  This package 
was placed in a FedEx Diagnostic Envelope.  
 
Our goal was to have samples arrive at the laboratory within 96 hours of collection, and 
received by 10:00 a.m. for processing.  After collection and packaging, field interviewers 
were required to place the packaged box inside of their soft-side cooler until they could 
get to a manned Federal Express office or until Federal Express could collect the 
package. If the field interviewer could not get to a Federal Express office before the end 
of the day, or if the Federal Express office was closed (as in the case of holidays or 
Sundays), field interviewers were asked to keep the packaged containers in their 
refrigerators until the following day.  
 
A unique challenge faced by the project was the closing of the Federal Express service 
and airports in the week following the September 11, 2001 attack on the World Trade 
Center and the Pentagon.  During this time, field interviewers were instructed to keep all 
the specimens that were collected in their refrigerator and to ship as soon as airports re-
opened and the Federal Express service re-initiated.  Despite these shipping delays, the 
project team decided to maintain the field work operation active, to the extent possible. 
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Notification Issues 
Research subjects who have participated in the Add Health Study are protected by a 
Certificate of Confidentiality issued by the Department of Health and Human Services in 
accordance with the provisions of section 301 (d) of the Public Health Service Act (42 
U.S.C.,241(d)).  Under the terms of the Confidentiality Certificate, UNC-CH, the 
Principal Investigator, and research staff are authorized to protect the privacy of the 
individuals who are the subjects of the Add Health project by withholding their 
identifying characteristics from all persons not connected with the conduct of the study.  
 
Collection of biological specimens and testing for STIs was handled in a manner 
consistent with the Add Health Security Management Protocol.  In order to remove the 
link between the biospecimen sample and the respondent’s identifying information, a 
specimen identification number was pre-assigned for each Add Health respondent by the 
Add Health Security Manager in Canada.  These specimen identification numbers were 
referred to as the UID, which was unique and different from the respondent’s 
questionnaire identification number.  The UID for each case was pre-loaded into the 
laptop computers used in the field interview process.  At the time of biospecimen 
collection, the link between the respondent identification number and the UID was 
broken.  The biospecimen sample was labeled using a barcode label that contained only 
the UID, and the connection between the respondent identification information and the 
UID was erased in the electronic files.   
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This protocol results in anonymous testing because HIV and STI results are never linked 
to a respondent’s identifying information.  At the end of specimen collection, respondents 
were told that the results of tests would be available by calling a toll-free number one 
month after the date of collection, and that they would be the only one who could access 
their results. To be sure no one else could receive their results, they were asked to select a 
password which they directly entered into the computer.  All respondents were given a 
card with the toll-free number, their UID, and a hand-written date that represented when 
their results should be available.  Respondents were told they would not be able to get 
their results without this information, and to keep the card in a safe place.  
 
The UID and password information for each Add Health respondent was transmitted 
electronically to Research Triangle Institute (RTI).  RTI transmitted this information to 
the American Social Health Association (ASHA) who maintained a toll-free telephone 
results and counseling service for the duration of the study. This information was stored 
by ASHA until such time that they received STI and HIV results from the UNC Labs for 
these cases (linked by the UID).  
 
The ASHA results and counseling telephone service was open from 3:00 PM to 11:00 
PM Eastern time five days a week.  Three telephone counselors were available at all 
times.  Respondents who called were asked to provide their UID and personal password.  
Once the counselor confirmed that the information was correct, the counselor provided 
the respondent with the available test results.  A respondent was able to refuse to receive 
one or all of the results at any time during the call.  The respondent was permitted to call 
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and receive his/her results twice.  The ASHA counselor also provided counseling, referral 
information, and the National CDC AIDS and STD Hotline telephone number [2].  All 
respondents with a positive test were told to seek health care.  Respondents were 
counseled to be re-tested at a health care facility if: 1) their Add Health HIV test was 
positive; 2) any test result was indeterminate; 3) any procedural problem occurred during 
specimen collection, transportation, or testing; 4) they suspected test results were wrong; 
or 5) they could not get test results because of a lost UID or forgotten password.  
Respondents who did not call for positive results had a second opportunity to learn results 
if contacted during follow-up HIV and STI notification interviews.  
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Chapter IV:  Laboratory Testing for Sexually Transmitted Infections 
 
Human Immunodeficiency Virus Type 1 (HIV-1) testing 
John L. Schmitz, Ph.D. 
Department of Pathology and Laboratory Medicine 
University of North Carolina 
 
Wave III respondents who provided consent were tested for the presence of antibodies to 
HIV-1 in oral mucosal transudate (OMT) specimens collected with the OraSureP
®
P HIV-1 
Oral specimen collection device (Epitope, Beaverton, OR).   
 
Upon receipt in the laboratory, OMT samples were inspected for the presence of a bar 
code label encoding the subjects’ UID number and a corresponding requisition with the 
same UID bar code label affixed.  After verification of the UID and collection date, the 
tip of the OraSure vial was broken off, the vial placed into a polypropylene centrifuge 
tube labeled with the corresponding UID and the sample centrifuged for 15 minutes at 
600 x g.  After centrifugation, the OraSureP
®
P collection device was discarded and the 
sample volume was verified to be at least 750 l.  Samples with less than 750 l were not 
tested as per the manufacturer’s instructions.  The centrifuged tubes were then capped 
and stored at room temperature until testing for HIV-1 antibodies was conducted, 
typically on the next day’s run. 
 
OMT samples were tested for the presence of HIV-1 antibodies using the Oral Fluid 
VironostikaP
® 
PHIV-1 Microelisa System (Organon Teknika Corporation, Durham, NC) 
following the manufacturer’s instructions.  Each run of microelisas contained 3 negative 
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and 1 positive controls.  The direct manual method was used to dilute controls and 
specimens directly in the wells of the microtiter plate that were coated with inactivated 
HIV-1 antigen.  After mixing, the plates were covered with an adhesive plate sealer and 
incubated at 37P
o
PC for 90 to 100 minutes.  The plates were then washed four times with an 
automated plate washer (ELP-40 Microplate Strip Washer, BIO-TEK, Instruments, Inc., 
Winooski, VT), followed by the addition of appropriately diluted peroxidase-conjugated 
goat anti-human immunoglobulin.  The plates were covered and incubated at 37P
o
PC for 30 
to 35 minutes followed by 4 washes.  One hundred and fifty microliters of ABTS (2,2’-
azino-di-[3-ethylbenzthiazoline-6-sulfonate]) substrate was then added and the plates 
incubated for 10 to 12 minutes uncovered.  Finally, 150 l of stop solution was added.  
The plates were mixed and the absorbance of each well determined with an automated 
microelisa plate reader (ELx800, BIO-TEK Instruments, Inc., Winooski, VT) at 405nm. 
 
The microelisa plate reader automatically determined assay acceptability and the positive 
cutoff value based on the negative and positive control absorbance values.  OMT samples 
with an absorbance value above the positive cutoff (reactive samples) were retested in 
duplicate wells of the microelisa assay on the next run of the test.  If either or both of the 
duplicate wells gave a positive result the sample was considered repeatedly reactive and a 
confirmatory Western immunoblot assay was performed. 
 
To confirm repeatedly reactive microelisa results, we used the OraSure P
®
P HIV-1 Western 
Blot Kit (Organon Teknika Corporation, Durham, NC), testing samples according to the 
manufacturer’s instructions.  Each run of blots contained one negative, one weak positive 
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and one strong positive control sera.  The on-strip dilution method was used to add 
controls and repeatedly reactive samples to the troughs of trays containing nitrocellulose 
strips with preblotted HIV-1 proteins.  After control and sample addition, the trays were 
covered and incubated for 3 hours at room temperature while rotating at 60 revolutions 
per minute (rpm).  Following incubation, the diluted controls and samples were aspirated 
and 2ml of sample buffer were added to each trough of the tray.  Sample buffer was 
immediately aspirated.  This procedure was repeated 2 more times, followed by two five-
minute washes in sample buffer.  Next, an alkaline phosphatase conjugated, goat anti-
human IgG (heavy and light chains) F(ab’)2 fragment was added to each trough of the 
tray, which was then covered and incubated for 45 minutes at room temperature with 
rotation at 60rpm.  The previously described wash procedure was then performed 
followed by a 5-minute wash in deionized water.  One milliliter of substrate (BCIP/NBT) 
was added to each trough of the tray, which was then mixed by hand and incubated 10 
minutes at room temperature.  Color development was stopped by rinsing the strips 3 
times in deionized water, followed by a 5-minute wash in deionized water.  The strips 
were then air-dried and banding patterns recorded on worksheets.  Criteria for acceptable 
runs as defined by the manufacturer were reviewed for each run.  If the criteria were not 
met, the entire run was repeated.   
 
Western blots were interpreted according to the following criteria:  A blot was defined as 
negative if no bands were present.  A blot was defined as positive if 2 or 3 bands 
corresponding to the p24, p41 or gp120/160 were present.  Any banding pattern not 
meeting this criterion was defined as indeterminate. 
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OMT specimens with a negative ELISA result on initial testing were reported as 
seronegative for antibodies to HIV-1 as were specimens that were reactive on the initial 
run but for which both duplicate repeat tests were negative.  In addition, specimens 
repeatedly reactive by ELISA but demonstrating no bands by Western blot testing were 
also reported as seronegative.  OMT specimens that were repeatedly reactive by ELISA 
and met the criteria for a positive Western blot were reported as seropositive for 
antibodies to HIV-1.  OMT specimens that were repeatedly reactive by ELISA but did 
not demonstrate a banding pattern meeting the criteria for a positive Western blot were 
reported as indeterminate. 
 
HIV-1 antibody testing by the OraSureP
®
P method was only conducted on specimens that 
were properly labeled (i.e., labeled with a bar-coded UID label on the transport vial and a 
corresponding UID barcode label on the accompanying requisition).  Any samples that 
were received with incomplete or no labeling were discarded and not tested.  
Additionally, as per the manufacturer’s instructions, OraSure P®P samples were required to 
be maintained at 4 – 37PoPC and tested within 21 days of collection.  Samples that were 
received beyond the 21-day time limit were not tested.  Specimen temperature was 
maintained by the inclusion of ice packs in the packing containers used for shipping.  All 
OraSureP
®
P samples were discarded after testing was completed. 
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Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) Testing 
John L. Schmitz, Ph.D. 
Department of Pathology and Laboratory Medicine 
University of North Carolina 
 
Wave III respondents who provided consent were tested for the presence of CT and GC 
DNA in urine specimens.  Urine was collected and shipped to UNC laboratories as 
described in Chapter III.  Urine sample requirements for CT and GC LCR testing were 
more restrictive than for HIV-1 antibody testing and are described below: 
 
Upon receipt in the laboratory, urine specimens were inspected for the presence of a bar 
code label encoding the subject’s UID number.  This UID number must have matched the 
UID bar code label affixed to the requisition accompanying the specimen.  After 
verification of the UID, volume of urine received, determination that the sample was cold 
and had been received within 4 days of collection, the urine was processed for CT and 
GC testing.  Additional aliquots of urine were processed for long-term storage and 
furtherl testing for Trichomonas vaginalis, Mycoplasma genitalium and human 
papillomavirus. 
Criteria for urine collection. 
 First void sample, collected at least 1 hour after the respondent had previously 
urinated. 
 20ml maximum volume collected.   
 Urine samples were placed in coolers with ice packs immediately after collection 
and shipped in packaging containing 2 ice packs.   
 Samples were received in the laboratory and processed within 4 days of collection. 
 Samples were shipped on the day of collection or the following day by overnight 
express to arrive in the laboratory by 10:00am.  Samples collected on Friday 
evenings or Saturdays were held at refrigerated temperature until shipment on the 
following Monday.  These samples arrived at the laboratory in sufficient time to 
meet the 4-day sample-processing requirement. 
 All samples, except those with improper labeling, were tested.   
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CT and GC testing was performed by Ligase Chain Reaction (LCR) testing (Abbott LCx 
Probe System, Abbott Park, IL).  A one-milliliter aliquot of urine was processed with the 
Urine Specimen Preparation Kit (Abbott LCx Probe System, Abbott Park, IL) following 
the manufacturer’s instructions.  Briefly, 1ml of well-mixed urine was added to a 
microfuge tube and centrifuged at 9,000 x g for 15 minutes at room temperature.  The 
supernatant was aspirated and 1ml of LCx Urine Specimen Resuspension Buffer was 
added to the remaining pellet.  The microfuge tubes were then vortexed to dislodge the 
pellet and heated at 97P
o
PC for 15 minutes, pulse-centrifuged and tested immediately or on 
the next days run.  For amplification, 100 l of processed urine was added to individual 
LCx Chlamydia and LCx Gonorrhoeae Amplification Vials.  Along with the respondent 
samples, 2 negative controls, 2 calibrators, and 1 positive control were prepared.  Vials 
were placed into thermocyclers and amplification was carried out under assay-defined 
parameters.  After amplification, controls, calibrators and respondent samples were 
placed into carousels for detection on the LCx microparticle enzyme immunoassay 
(MEIA) detection instrument.   
 
In the presence of amplified CT and/or GC DNA in the respondent, 2 pairs of pathogen 
specific probes bind and are ligated.  Probes (ligated and unligated) are captured onto 
microparticles via an antibody to the capture hapten on one end of the ligated probe.  
After a wash step, bound, ligated probes (only produced in samples with CT or GC DNA) 
are specifically identified by reaction with a second, alkaline phosphatase conjugate 
antibody that binds to the detection hapten on the other end of the ligated probe.  
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Unligated but bound probes are not detected as they have no detection hapten on the 
other end of the probe.  The presence of bound antibody is detected by adding the 
substrate (4-Methylumbelliferyl Phosphate), which results in the generation of a 
fluorescent signal detected by the LCx instrument. 
 
To determine whether a sample contains CT and/or GC DNA, the LCx detection 
instrument determines a cutoff value for each run based on calibrator rates.  A signal-to-
cutoff (S/CO) ratio is then determined for each sample in the assay run.  The following 
criteria were used to determine the final results of each respondent sample (for both CT 
and GC) based on the S/CO ratio, and a summary of results is presented below. 
 
Initial S/CO <0.80:  Negative for CT and/or GC 
Initial S/CO >0.80:  All samples with this S/CO were repeat tested 
Repeat S/CO >1.00:  Positive for CT and/or GC 
Repeat S/CO <1.00:  Negative for CT and/or GC 
 
 
 
 
 
 
 
 
Table 1:  Laboratory testing for Chlamydia trachomatis and Neisseria gonorrhoeae 
 
Laboratory result Chlamydia trachomatis Neisseria gonorrhoeae 
Positive      645        57 
Negative 12,668 12,339 
No results      699   1,616 
Refused   1,185 1,185 
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Trichomonas vaginalis testing 
Marcia M. Hobbs, Ph.D. 
Research Associate Professor of Medicine, Microbiology & Immunology 
University of North Carolina 
 
Urines were tested using an in-house PCR-ELISA that detects Trichomonas vaginalis 
DNA.  This T. vaginalis PCR-ELISA is not FDA approved and is currently used for 
research purposes only.  However, formal validation studies of the performance of the 
assay compared to wet mount and culture are published in the Journal of Clinical 
Microbiology [1,2] and described in the next section.  The PCR primers used in this 
assay, TVK3 and TVK7, specifically amplify a 312-bp sequence from repetitive DNA in 
the T. vaginalis genome.  PCR with these primers is negative with human DNA, other 
organisms found in the genitourinary tract and other Trichomonas species [3].  PCR 
products were detected using an ELISA format with a nucleotide probe (TVK) that binds 
a specific DNA sequence in the amplified product from positive specimens.  Results were 
determined from absorbance values that ranged from 0 to 3.5.  Based on the published 
ROC analysis of the test in urine from women, an ELISA absorbance cutoff of 3.0 was 
used to determine a positive result for specimens from female subjects.  The published 
ROC analysis of the test in urine from men established 2.0 as the cutoff for male subjects.  
Negative test results were coded 0, and positive test results were coded 1.   
 
Using a modification of the published assay procedures [1,2] Add Health urine specimens 
were tested using the specifics outlined below.  Urine specimens were received and 
logged into the computer system in the UNC Hospitals Clinical Microbiology/ 
Immunology Laboratories.  A 1ml aliquot of each sample was labeled with the UID 
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number, and samples were transported to the Sexually Transmitted Disease Cooperative 
Research Center (STD CRC) Microbiology Core Laboratory for T. vaginalis testing.  
Samples were prepared within 2 days of receipt using the Amplicor CT/NG Urine 
Specimen Prep kit (Roche Diagnostic Systems, Indianapolis, IN) according to the 
manufacturer’s instructions.  Urine preps were stored at –70ºC until PCR-ELISA testing. 
 
For PCR, 50 l of thawed urine prep was used as template in a reaction containing 40 
pmol each of primers TVK3 and TVK7 (digoxigenin [DIG] labeled), 200 mM each 
dATP, dCTP, dGTP and dUTP, 2.5 U Taq polymerase (Gibco BRL, Grand Island, NY) 
4mM MgClB2B and 1.0 U AmpErase (uracil N-glycosylase; Applied Biosystems, Foster 
City, CA) in 1x PCR buffer (Gibco BRL) in a final volume of 0.1 ml.  PCR consisted of 
an initial 5-min incubation at 95ºC followed by 40 cycles of denaturation at 90ºC for 1 
min, annealing at 60ºC for 30 sec, and extension at 72ºC for 2 min.  Purified T. vaginalis 
DNA and sterile water were used as positive and negative controls with every batch of 
PCR tests.   
 
PCR products were detected using the PCR ELISA DIG detection kit (Roche Diagnostic 
Systems) according to the manufacturer’s instructions.  For ELISA, 60 l of PCR product 
was incubated with 50 ng of biotinylated TVK probe in hybridization buffer in a final 
volume of 1.0ml; 200 l of the hybridization solution was pipetted into streptavidin-
coated wells of the kit microtiter plate and incubated at 37ºC for 2 h. with gentle rocking.  
Plates were washed 5 times in a microtiter plate washer containing kit washing solution, 
and 200 l of anti-DIG POD solution (diluted as per kit instructions) was added to each 
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well and incubated at 37ºC for 30 min. with gentle rocking.  Plates were washed as 
above, and 200 l of ABTS substrate solution was added to each well and incubated at 
37ºC in the dark for 1 h. with gentle rocking.  Absorbance was read at 405nm in a 
spectrophotometric plate reader with a linear range up to 3.5; absorbance of the kit 
negative control read at 492 nm was subtracted from sample readings as directed in the 
kit instructions.  Tests were considered valid if the absorbance of the positive control was 
> 2.0 and the negative control was < 0.2.  Duplicate values for individual specimens were 
averaged and, based on the published ROC analyses of the test in urine, ELISA 
absorbance values (Abs) of 3.0 for specimens from women and 2.0 for specimens from 
men were used as cutoffs.  Indeterminate results were not possible, and positive results 
were not verified by re-testing.  Below is a summary of results. 
 
 
 
 
 
Human papillomavirus (HPV) testing 
Nancy B. Kiviat, M.D. 
Professor of Pathology 
University of Washington 
 
Qinghua Feng, Ph.D. 
Research Scientist 
University of Washington 
 
HPV test result data will be made available in the second release of Wave III data 
scheduled for the Fall of 2003. 
Table 2:  Laboratory testing for Trichomonas vaginalis 
 
 Positive Negative No results Refused 
Trichomonas vaginalis 340 12,869 803 1,185 
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Five ml aliquots of urine were flagged and shipped to the University of Washington and 
selected for HPV testing as described in Chapter 2.  Upon receipt of the shipment, sample 
volume, condition, and receipt date were recorded.  An additional internal lab number 
was assigned and used for DNA preparation, PCR amplification and dot blot detection.  
All samples were catalogued, thawed, and two 2.5 ml aliquots prepared.  If there were 
less than 5 ml in the tube, the amount of sample was divided evenly into two aliquots.  
One aliquot was retained in the HPV laboratory for HPV testing and the other was re-
frozen and forwarded to the M. genitalium laboratory for M. genitalium testing.   
 
An experimental, non-commercial polymerase chain reaction (PCR)/Dot blot test was 
used to identify the presence of genital HPV DNA in the urine specimen, irrespective of 
HPV type.  The urine specimen was thawed, aliquoted and spun to collect the urine 
pellet.  The urine pellet was resuspended in 600 l STM (storage and transfer media from 
Digene) and digested with 20 g/ml protease K.  Genomic HPV DNA was isolated from 
100 l of the digested urine pellet using QIAamp blood DNA mini column.  DNA from 
each sample was amplified using HPV L1 consensus primers MY09/MY11/HMB01 and 
beta-globin primers PC04/GH20 [4].  The amplification mixture contained 6 mM MgCl2, 
1x PCR buffer II, 7.5 U Gold Tag DNA polymerase (AmpliTaq Gold, Roche Molecular 
Diagnostics, Cat. No. N808-0249), 200 M dNTPs, 50 pmole MY09 and MY11 primers, 
10 pmole HMB01, PC04 and GH20 primers and 50-100 ng template DNA in 50 l.  The 
DNA was amplified using the following program: 95°C, 9 min; 95°C, 20 sec, 55°C, 30 
sec, 72°C, 30 sec for 40 cycles; 72°C, 10 min.  Ten microliter PCR products were then 
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dotted onto two nylon filters and probed with biotin-labeled beta-globin and HPV generic 
probes respectively.  The dot blot results were read by two persons independently and 
any discrepancies resolved by a third individual’s interpretation.  
 
Beta-globin, a housekeeping gene, was used to monitor sample sufficiency and PCR 
amplification.  When present, it indicates that sufficient cellular DNA is present and that 
amplification is occurring (e.g., the sample is not inhibited), and, when absent, it 
identified samples that were insufficient for analysis.  Thus, recorded results indicated 
whether the specimen was positive for beta-globin and HPV.  If the beta-globin result 
was negative, the HPV result was inconclusive and those samples were excluded.  No re-
testing of positive samples was performed. 
 
 
Mycoplasma genitalium (MG) testing 
Patricia A. Totten, Ph.D. 
Research Associate Professor 
University of Washington 
 
Although a general description of methods for M. genitalium PCR testing is presented 
here, more details will be provided with publication of the development and validation of 
this test (SM Dutro, JK Hebb, CA Garin, JP Hughes, GE Kenny and PA Totten, 
submitted).  Data on M. genitalium test results will also be available in the second release 
of Wave III data scheduled for Fall 2003.   
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Samples to be tested for M. genitalium were received first in the HPV laboratory, thawed, 
aliquoted, and frozen at –80  until preparation.  After thawing, samples were processed 
using the AMPLICORP P CT/NG specimen preparation kit, according to manufacturer’s 
directions (Roche Diagnostics Corporation, Indianapolis, IN, ―urine procedure‖).  To test 
the subset of samples for M. genitalium, we used an M. genitalium-specific PCR assay 
targeting the MgPa genes as described [5] with modifications for the detection of PCR 
products using a microwell plate rather than a Southern blot based assay (SM Dutro, JK 
Hebb, CA Garin, JP Hughes, GE Kenny and PA Totten, submitted).  This experimental, 
non-commercial assay is not FDA approved.  Briefly, the PCR assay targets the MgPa 
genes of M. genitalium using the previously described primer sets, 5'-
TGAAACCTTAACCCCTTGG-3' and 5'-AGGGGTTTTCCATTTTTGC-3' [5], except 
that the primers were biotinylated in the current assay to allow attachment to streptavidin-
coated plates.  M. genitalium-specific PCR products were allowed to hybridize to a 
digoxigenin-labeled probe DNA, which was subsequently detected using the PCR ELISA 
DIG detection kit (Roche Diagnostic Systems).  Cutoffs, determined by ROC analysis, 
were used to score tests as positive or negative (SM Dutro, JK Hebb, CA Garin, JP 
Hughes, GE Kenny and PA Totten, submitted).  All positive and equivocal specimens 
were confirmed as positive if they repeated with one positive or two equivocal results 
upon repeat in duplicate using the same MgPa PCR assay.  All negative specimens were 
not retested and reported as negative.  Positive controls and negative controls for the 
whole procedure, including sample preparation (M. genitalium whole cells and sample 
preparation reagents alone) as well as the PCR assay alone (M. genitalium genomic DNA 
 30 
and sterile water) were included in every batch of PCR assays and required to have the 
expected result for a valid run. 
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Test characteristics, measured prevalence, and estimated true prevalence 
The tests used for the identification of HIV and sexually transmitted infections are 
imperfect, with sensitivities and specificities less than 1.  Estimation of the prevalence of 
these infections and associations with various potential risk factors will be affected by the 
test performance.  The magnitude of these effects will depend on the performance 
characteristics of the tests and the prevalence of the disease in the population.  Previous 
estimates of test performance can be used to guide analyses of the potential effects of the 
use of these imperfect tests. 
 
The results of previous studies assessing test performance must be applied cautiously to 
the Add Health population.  The study population of Wave III of Add Health is 
community-based, rather than clinic-based.  Consequently, the prevalence of HIV 
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infection and most STIs is expected to be relatively low, certainly lower than most clinic 
populations.  Furthermore, the majority of infections will be asymptomatic.  In contrast, 
the majority of the tests used in the Add Health study were evaluated in clinic-based 
populations, frequently in symptomatic persons.  The presence of symptoms is often 
related to the organism burden.  Sensitivity of the diagnostic tests tends to be lower with 
lower organism burden.   
 
The combination of low prevalence and imperfect diagnostic tests leads to more 
substantial measurement error than would be encountered in higher prevalence 
populations.  The magnitude of the measurement error can be estimated using a simple 
formula that relies on estimates of the sensitivity and specificity. 
 
    Measured Prevalence +  Specificity – 1 
True Prevalence Estimate =    -------------------------------------------------------------- 
     Sensitivity + Specificity – 1 
 
For example, given sensitivity of 90%, specificity of 99.5%, and measured prevalence of 
1%, the prevalence estimate would be: 
 
True Prevalence estimate = (0.01 + 0.995 – 1)/(0.90 + 0.995 – 1) = 0.0056 or 0.56% 
 
Generally, in the range of the sensitivities and specificities of the tests used in this study 
and the expected prevalences of the STIs, the specificity has the greatest effect on the 
 33 
measured prevalence (Figures 1 & 2).  One important feature to note is that the measured 
prevalence cannot be below a certain level with a given specificity. Thus, it may be 
possible to argue that a test performed with higher specificity than previously estimated 
because of the measured prevalence. This possibility highlights the fact that the actual 
performance of a diagnostic test is never certain within the context of a given research 
study. 
 
Test Characteristics 
The tests used in Add Health have all been validated in other populations.  However, the 
generalizability of the validation study populations, which are typically clinic-based, to 
the largely asymptomatic general population of 18-26 year olds in Add Health varies.  
Furthermore, the methodological issues related to test validation for some of these assays 
are substantial, leading to further uncertainty in the test characteristics. 
 
The diagnostic tests used for the identification of Chlamydia trachomatis (CT), Neisseria 
gonorrhoeae (GC), Trichomonas vaginalis (TV), human papillomavirus (HPV) and 
Mycoplasma genitalium (MG) are nucleic acid amplification tests (NAAT).  Assessing 
the performance of NAAT is problematic because no perfect reference standard exists 
and, in many cases, the new NAAT tests are considerably more sensitive than the 
traditional reference standard, culture.  Various methods have been used to overcome the 
reference test bias, but none of the commonly used methods are completely satisfactory 
[1].  Thus, the performance characteristics of NAATs used in Add Health are uncertain.  
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Still, the results of previous studies provide a reasonable starting place for considering the 
test performance. 
 
CT LCR Assay:  The package insert for the Abbott LCx Assay reports a sensitivity of 
94.1% and specificity of 95.2% in urine for asymptomatic women.  In asymptomatic 
men, the sensitivity and specificity are reported as 90.0% and 97.9%, respectively.  These 
estimates of the specificity are likely to be underestimates due to poor sensitivity of the 
reference standard. 
 
In a recent meta-analysis, four studies of the performance of urine-based LCR for CT in 
asymptomatic men and women were identified [2].  The sensitivity ranged from 87.5 – 
96%.  The specificities were all reported as 100%, although these estimates were based 
on discrepant analysis, a biased procedure known to lead to overestimation of test 
performance.  A recent large study in men that used a combination of tests as the 
reference standard estimated the sensitivity as 80.4 – 89.3% and specificity as 95.5 – 
99.6% [3].  A similar study in women revealed sensitivity of 80.8% – 83.4% and 
specificity of 97.8% – 98.9% [4].  The imperfect sensitivity of the combined reference 
standards of these studies may result in a slight underestimation of specificity.   
 
GC LCR Assay:  The package insert for the Abbott LCx Assay reports a sensitivity of 
100.0% and specificity of 98.5% in urine for asymptomatic women.  In asymptomatic 
men, the sensitivity and specificity are reported as 100.0% and 100.0% respectively.  
However, these results are based on very small numbers of subjects.  The overall 
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sensitivity and specificity in combining symptomatic and asymptomatic men and women 
are calculated as 94.9% and 99.9%.  These estimates of the specificity are likely to be 
underestimates due to the imperfect sensitivity of the reference standard.   
 
In a systematic review of the performance of LCR for GC, the reported sensitivity in 
women was 94.3% - 100% and the specificity was 98.7% - 99.7% before discrepant 
analysis [5].  In men, the sensitivity was 98.0% - 100% and specificity 98.6 – 100%.  All 
studies reported specificities of 100% after discrepant analysis.  In the Add Health 
population, all GC tests with S/CO of  0.8 were repeated and confirmed positive only if 
repeat amplification yielded a S/CO of  1.0.  This procedure should improve specificity 
and reduce the number of false positives. 
 
TV PCR Assay: The TV PCR assay is available for research purposes only.  In the only 
evaluation studies to date, the assay performed with a sensitivity of 90.8% and adjusted 
specificity of 93.4% in women [6].  In men, the sensitivity was 88.9% and the adjusted 
specificity was 94.5% [7].  The sensitivities and specificities of the assay by symptom 
status are listed in Table 1.  These specificities were based on an algebraic adjustment of 
the observed specificities.  The specificities are undoubtedly lower than actual 
performance, even after adjustment, because of the very poor sensitivity of culture, the 
reference standard. 
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Table 1.  Performance of T. vaginalis PCR-ELISA compared to combined reference of wet mount and 
culture 
 
Subject group 
 
% Sensitivity (95% CI) 
 
Adjusted % SpecificityP
a
P
 
Symptomatic P
b
P
 89.5 (65.5, 98.2) 90.7 
Women   
Asymptomatic 91.8 (84.1, 96.2) 95.3 
   
   
Symptomatic P
c
P
 87.2 (73.6, 94.7) 97.5 
Men   
Asymptomatic 90.9 (74.5, 97.6) 92.7 
P
a 
PAdjusted specificity using the formula of Staquet et al. (J. Chron. Dis. 34:599-610; 1981); assumes wet 
mount /culture has sensitivity of 70% for women and 50% for men. 
 
P
b
PAbnormal vaginal discharge. 
 
P
c
PUrethritis >4 wbc/hpf on urethral gram stain. 
 
 
The limit of detection for T. vaginalis PCR-ELISA is 8 organisms per PCR (160 
organisms per ml of urine).  These data are from urine specimens with volumes ranging 
from 2 to 100ml (mean 31.8 ml); the test is slightly more sensitive in specimens < 20ml 
for women (100.0%; 95%CI: 82.2, 100.0) and < 30 ml for men (92.75; 95% CI: 79.0, 
98.1).   
 
HPV PCR/dot blot hybridization assay:  The analytic limit of detection for this assay is 
one HPV molecule per sample.  For women, the assay is less sensitive in urine samples 
than it is in cervical swab samples because of the lower number of cervical epithelial 
cells and the greater amount of PCR inhibitors in urine.  To address this, Qiagen columns 
were used to purify DNA and eliminate inhibitors.  The assay may be less sensitive in 
men, because fewer HPV-containing epithelial cells are shed into urine, but remains 
specific.  The dot blot detection procedure is more specific than the FDA-approved 
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Digene hybrid capture assay, and the generic probe can detect a majority of the 40 
anogenital HPV types.   
 
MgPa PCR assay for M. genitalium:  The MgPa PCR assay is a new, experimental assay 
available for research purposes only.  The analytical sensitivity (limit of detection) is 1 
(with 38% confidence) and 15 (with 95% confidence) genome copies of M. genitalium.  
Since culture is extremely difficult for this fastidious organism, and alternative types of 
detection have not been developed, the sensitivity and specificity of the M. genitalium 
PCR has not been determined.  However, analysis of a subset of PCR positive and 
negative samples using another M. genitalium-specific PCR test or by sequencing the 
PCR product is consistent with high specificity of this assay [8, 9].  Nevertheless, the 
relative sensitivity and specificity of the M. genitalium PCR test using different specimen 
types, both from men (urethra vs. urine) and women (vagina vs. cervix vs. urine) requires 
further study.   
 
HIV Orasure Assay: The only published assessment of the HIV Orasure Assay was 
conducted among 3570 subjects from a variety of settings (blood banks, clinics, and 
others) [10].  Among 673 HIV positive persons, 665 were identified as positive by the 
Orasure assay (sensitivity=0.988).  The specificity was 0.9986, based on 2880 negative 
EIA results, 13 EIA positive/WB negative, and 4 EIA positive/WB indeterminate results 
among a population of 2897 HIV negative persons. 
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Figure 1.  The relationship between measured prevalence and estimated actual prevalence 
with varying specificity.  Sensitivity is held constant at 0.85. 
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Figure 2. The relationship between measured prevalence and estimated actual prevalence 
with varying sensitivity.  Specificity is held constant at 0.85. 
 
 
0.000
0.010
0.020
0.030
0.040
0.050
0.060
0.070
0.080
0.090
0.100
0.110
0.120
0.000 0.010 0.020 0.030 0.040 0.050 0.060 0.070 0.080 0.090 0.100
Measured Prevalence
E
s
ti
m
a
te
d
 A
c
tu
a
l 
P
re
v
a
le
n
c
e
Sensitivity=0.80
Sensitivity=0.85
Sensitivity=0.90
Sensitivity=0.95
Sensitivity=0.99
 40 
REFERENCES 
1. Miller, WC.  Can we do better than discrepant analysis for new diagnostic test 
evaluation?  Clin Infect Dis 1998;27(5):1186-93. 
2. Watson EJ, Templeton A, Russell I, Paavonen J, Mardh PA, Stary A, Pederson BS.  
The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic 
review.  J Med Microbiol 2002;51(12):1021-31. 
3. Johnson RE, Green TA, Schachter J, Jones RB, Hook EW 3rd, Black CM, Martin 
DH, St Louis ME, Stamm WE.  Evaluation of nucleic acid amplification tests as 
reference tests for Chlamydia trachomatis infections in asymptomatic men.  J Med 
Microbiol 2002;51(12):1021-31. 
4. Black CM, et al. Head-to-head multicenter comparison of DNA probe and nucleic 
acid amplification tests for Chlamydia trachomatis infection in women performed 
with an improved reference standard. J. Clin. Microbiol. 2002;40:3757-3763. 
5. Koumans EH, Johnson RE, Knapp JS, St Louis ME.  Laboratory testing for Neisseria 
gonorrhoeae by recently introduced nonculture tests: a performance review with 
clinical and public health considerations.  Clin Infect Dis 1998;27(5):1171-80. 
6. Kaydos SC, Swygard H, Wise SL, Sena AC, Leone PA, Miller WC, Cohen MS, 
Hobbs MM.  Development and validation of a PCR-based enzyme-linked 
immunosorbent assay with urine for use in clinical research settings to detect 
Trichomonas vaginalis in women.  J Clin Microbiol 2002;40(1):89-95 
7. Kaydos-Daniels SC, Miller WC, Hoffman I, Banda T, Dzinyemba W, Martinson F, 
Cohen MS, Hobbs MM.  Validation of a urine-based PCR-enzyme-linked 
 41 
immunosorbent assay for use in clinical research settings to detect Trichomonas 
vaginalis in men.  J Clin Microbiol 2003;41(1):318-23. 
8. Cohen CR, Manhart LE, Bukusi EA, Astete S, Brunham RC, Holmes KK, Sinei SK, 
Bwayo JJ, Totten PA.  Association between Mycoplasma genitalium and acute 
endometritis.  Lancet 2002;359(9308):765-6.   
9. Manhart LE, Critchlow CW, Holmes KK, Dutro SM, Eschenbach DA, Stevens CE, 
Totten PA.  Mucopurulent cervicitis and Mycoplasma genitalium.  J Infect Dis 
2003;187(4):650-7. 
10. Gallo D, George JR, Fitchen JH, Goldstein AS, Hindahl MS.  Evaluation of a system 
using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. 
OraSure HIV Clinical Trials Group.  JAMA 1997;277(3):254-8. 
 42 
Chapter VI – DNA sampling, genotyping, and determination of zygosity. 
Andrew Smolen, PhD 
Institute for Behavioral Genetics 
University of Colorado 
Boulder, CO 80309 
 
John K. Hewitt, PhD 
Institute for Behavioral Genetics 
University of Colorado 
Boulder, CO 80309 
 
 
 
Introduction 
Respondents identified as full siblings or twins at earlier waves (n=3,787) were asked to 
supply saliva specimens for DNA analysis as described in Chapter 2, and researchers at 
the University of Colorado are conducting genetic analyses on these biospecimens.  Data 
generated from these analyses will enable behavior genetic studies of adolescent health to 
move from variance decomposition into anonymous components, to the testing of 
specific hypotheses about the influence of individual genes and their expression in the 
context of environmental circumstances.  Beyond the specific candidate genes identified 
for study, DNA collection in conjunction with the rich phenotypic and environmental 
data gathered in the Add Health project creates an important research resource for future 
studies. 
 
Saliva samples were collected from full siblings or twins to genotype DNA for seven 
candidate polymorphisms.  These candidate genes have been reported to be associated 
with individual differences in behavior related to mental health; are reported to be 
functional, exonic, in promoter regions, or affect gene expression; are expressed in the 
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brain; and have prima facie involvement in neurotransmission.  The initially targeted 
candidates are the dopamine transporter (DAT1), the dopamine D4 receptor (DRD4), the 
serotonin transporter (5HTT), monoamine oxidase A (MAOA), monoamine oxidase B 
(MAOB), the dopamine D2 receptor (DRD2), and the dopamine D5 receptor (DRD5).  
The laboratory methods for the three primary candidates (DAT1, DRD4, 5HTT) are 
described below.  Genotyping for 11 neutral markers for the purposes of zygosity 
determination will also be conducted where needed. 
 
Field collection methods 
Respondents who were selected for this sample were asked to read and sign separate 
informed consent forms and there was no incentive payment for providing a DNA 
specimen.  The respondent was asked to insert one sterile cytology brush into the mouth 
and rub the cheeks and gums for 20 seconds to collect buccal cells.  The tip of the brush 
was placed in a 2 ml screw cap tube containing 200 µl of lysis buffer (1% isopropyl 
alcohol [v/v] in 50 mM Tris-HCl, 1 mM EDTA and 1% sodium dodecyl sulfate, pH 8.0).  
The subjects then swished their mouths with 10 ml of 4% sucrose vigorously for 30 sec, 
and the contents were discharged into a 50 ml conical test tube which was sealed with 
parafilm (―wash 1‖).  This was followed by a second mouth wash done identically (―wash 
2‖).  The tubes were labeled and packaged for shipment with ice packs to maintain a 
temperature of 4P
o
PC until received in the University of Arizona laboratory for DNA 
extraction.  Specimens were later transferred to the University of Colorado for genetic 
typing and analysis.   
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Laboratory methods 
DNA Samples. DNA samples were prepared in the laboratory of Dr. David Rowe, 
University of Arizona.  Genomic DNA was isolated from buccal cells using a 
modification of published methods [1-4].  The brush and mouthwash samples were 
prepared separately, and combined at a later stage.  On day one, 1 ml of lysis buffer (6 M 
guanidine-HCl, 100 mM Tris-HCl and 10 mM EDTA, pH 7.5) and 25 µl of proteinase K 
(10mg/ml) were added to each 2 ml tube containing the swab. Tubes were placed in a 
rotator in a 55°C incubator overnight.  The  ―wash 1‖ and ―wash 2‖ samples were 
combined and centrifuged at 1,800 rev/min for 10 min at room temperature.  The 
supernatant was discarded, and 1 ml of lysis buffer was added to the resulting pellet.  The 
resuspended pellet was transferred to a fresh 2 ml tube, and 25 µl of proteinase K 
(10mg/ml) was added. Samples were placed in a rotating incubator overnight at 55°C. 
 
On day two, the brush heads were removed from their tubes, and 200 µl of binding 
matrix (10 mM sodium acetate and 0.1g/ml diatomaceous earth [Sigma] in lysis buffer) 
was added to each brush and wash tube.  The tubes were placed on a rotator at room 
temperature for 15 min, and centrifuged at maximum speed for 2 min.  The supernatant 
fluid was discarded, and 1 ml of wash buffer (50% ethanol [v/v] in 400 mM sodium 
chloride, 20 mM Tris-HCl and 2 mM EDTA, pH 7.5) was added to the pellets in each 
tube.  The tubes were placed on a rotator at room temperature for 15 min, and centrifuged 
at maximum speed for 2 min again.  The supernatant fluid was discarded and the 
resulting pellets were vacuum dried overnight. 
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On day three, 200 µl of elution buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.8) was 
added to each dried pellet.  The tubes were placed in a rotating incubator at 55 for 30 
min, and centrifuged at maximum speed for 2 min. The supernatant fluids from each 
individual’s brush and wash tubes were combined and stored in a single 0.5 ml tube. The 
yield of DNA was quantified by absorbance at 260 nm (1 O.D. = 50 µg/ml), and an 
aliquot was diluted to a concentration of 20 ng/µl or less for a working sample. The 
average yield of DNA was 58 ± 1 µg. DNA samples were stored at 4°C and transported 
to the Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado for 
genotyping. 
 
Genotyping. Initial screening of the samples included the analysis of three polymorphic 
candidate genes: the dopmaine transporter, the serotonin transporter and the dopamine D4 
receptor.  Additional genes identified are the dopamine D2 receptor gene, the monoamine 
oxidase A promoter, and the CYP2A6 gene. 
 
Dopamine transporter (DAT1, locus symbol: SLC6A3). The DAT1 gene, which maps 
to 5p15.3 [5] contains a 40 bp Variable Number Tandem Repeat (VNTR) polymorphism 
in the 3' untranslated region. This VNTR ranges from 3 to 11 copies, and has been 
reported to effect translation of the DAT protein in human striatum [6].  The 9-repeat 
(440 bp) and 10-repeat (480 bp) polymorphisms are the two most common alleles in 
Caucasian, Hispanic and African American populations [7].  The assay was a 
modification of the method of Vandenbergh et al [5]. The primer sequences were: 
forward, 5'-TGTGGTGTAGGGAACGGCCTGAG-3' (fluorescently labeled), and 
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reverse: 5'-CTTCCTGGAGGTCACGGCTCAAGG-3'. 
 
Dopamine D4 Receptor (DRD4). The DRD4 gene, which maps to 11p15.5, contains a 
48 bp VNTR in the third exon [8]. This VNTR can consist of 2 to 11 repeats, although 4 
and 7 are most common.  This polymorphism results in a variation in the third 
cytoplasmic loop of the receptor protein, which has been shown to affect the function of 
the D4 receptor in vivo [8].  The assay used was a modification of the method of Sander 
et al. [9].  The primer sequences [10] were: forward, 5'-AGGACCCTCATGGCCTTG-3' 
(fluorescently labeled), and reverse, 5'-GCGACTACGTGGTCTACTCG-3'.  This method 
results in PCR product of (in bp): 379, 427, 475 (4x), 523, 571, 619 (7x), 667, 715, 763 
and 811. 
 
Serotonin transporter (5HTT, locus symbol SLC6A4). The 5HTT gene, which maps to 
17q11.1-17q12, contains a 44 bp VNTR in the 5' regulatory region of the gene [11]. The 
VNTR in the promoter appears to be associated with variations in transcriptional activity: 
the long variant (528 bp) has approximately three times the basal activity of the shorter 
promoter (484 bp) with the deletion [12].  The assay used was a modification of the 
method of Lesch et al. [12].  The primer sequences were:  forward, 5'-
GGCGTTGCCGCTCTGAATGC-3' (fluorescently labeled), and reverse, 5'-
GAGGGACTGAGCTGGACAACCAC-3.'  These primer sequences yield products of 
484 or 528 bp. 
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Monoamine Oxidase A promoter (MAOA-uVNTR).  The MAOA gene, which maps to 
Xp11.3-11.4, contains a 30 bp Variable Number Tandem Repeat (VNTR) in the 5’ 
regulatory region of the gene [15] which has been shown to affect expression [16].  The 
MAOA gene product is primarily responsible for the degradation of dopamine, serotonin, 
and norepinephrine and is located in the nigro-striatial pathway of the brain [17,18].  A 
genotype by environment interaction has been reported for this polymorphism.  This 
finding has been both supported [20] and questioned [21,22]. 
 
The MAOA-uVNTR polymorphism was assayed by a minor modification [21] of a 
published method [16].  Primer sequences for the 30bp VNTR in the promoter region of 
the MAOA open reading frame were:  forward, 5’ACAGCCTGACCG-TGGAGAAG-3’ 
(fluorescently labeled), and reverse, 5’-GAACGTGACGCTCCATTCGGA-3’ [16].  PCR 
reactions contained 1 µl of DNA (20 ng or less), 1.8 mM MgCl2, 180 µM 
deoxynucleotides, with 7'-deaza-2'-deoxyGTP (Roche Applied Science, Indianapolis, IN) 
substituted for one-half of the dGTP, 200 nM forward and reverse primers (IDT, 
Coralville, IA) and 1 unit of AmpliTaq Gold® polymerase (PE-Biosystems, Foster City, 
CA), in a total volume of 20 µL.  Amplification was performed using a modified version 
of touchdown PCR [13] as detailed previously [14] and analyzed in an ABI Prism 3100 
Genetic Analyzer using protocols supplied by the company.  Products of this reaction 
included five possible fragment sizes that included 291, 321, 336, 351, and 381bps (2, 3, 
3.5, 4 and 5 repeats, respectively).  Genotypes were scored independently by two 
individuals.  
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DRD2 TaqIA (dbSNP reference:  rs1800497,  LocusID: 1813).  The gene encoding the 
dopamine D2 receptor maps to 11q23, and contains a number of genomic variations that 
include SNPs, di-nucleotide repeats, and restriction endonuclease sites in coding and non-
coding regions [23].  The dopamine D2 receptor gene (DRD2) has a polymorphic TaqI 
restriction endonuclease site about 2500 bp downstream (3' untranslated region) from the 
coding region of the gene.  This site is designated the TaqIA site to distinguish it from 
another TaqI restriction site (TaqIB) located elsewhere in the gene.  The A1 allele has a 
point mutation C→ T (TCGA to TTGA), which eliminates the TaqI site.  This is not a 
functional polymorphism as far as we know.  This polymorphism is generally assayed by 
incubating the full-length PCR product (304 bp) with TaqI enzyme.  Amplicons that do 
not contain the restriction site are not cleaved (TaqIA-1 allele).  Those that contain the 
restriction site are cleaved to 178 and 126 bp fragments (TaqIA-2 allele).  It has been 
reported that the TaqIA-1 allele is associated with severe alcoholism [24,23].  We 
redesigned the assay as a SNP assay using the Applied Biosystem’s  ―Taqman® Assays-
by-Design  for SNP Genotyping Service‖.  Primer and probe sequences are given in 
Table I. For this assay the T-containing probe 1, is equivalent to the TaqIA-1 allele, and 
the C-containing probe 2 is equivalent to the TaqIA-2 allele. 
 
The DRD2 TaqIA assay [25] was performed using the fluorogenic 5’nuclease  
(Taqman , Applied Biosystems, Foster City, CA) method using reagents (VIC  and 
FAM  labeled probes and TaqMan® Universal PCR Master Mix without AMPerase  
UNG) obtained from Applied Biosystems (ABI).  Unlabeled forward and reverse primers 
were purchased from ABI or Integrated DNA Technologies (Coralville, IA).  All 
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reactions were performed in an ABI Prism  7000 Sequence Detection System using the 
allelic discrimination mode as described by Livak [26] and in the accompanying 
instrument documentation.  Methods used were as described in the package inserts from 
ABI, except that the total reaction volume was decrease to 20 µl.  Reactions contained 1 
µl of DNA (approximately 20 ng of DNA), 8.5 µl of water, 0.5 µl of 40x primer/probe 
mix and 10 µl of 2x Taqman  Universal Master Mix.  Final primer and probe 
concentrations were 900 mM and 200 mM, respectively.  The seqences of primers and 
probes were: Forward Primer: 5’-GTGCAGCTCACTCCATCCT-3’; Reverse Primer:  5’-
GCAACACAGCCATCCTCAAAG-3’; Probe 1: 5’- VIC-CCTGCCTTGACCAGC-
NFQMGB-3’; Probe 2: 5’- FAM-CTGCCTCGACCAGC-NFQMGB-3’. Probe 1 
(VIC/NFQMGB) anneals to the ―T‖ form (―A‖on the opposite strand, TaqIA-1, no 
restriction site, 304 bp fragment) and probe 2 (FAM/NFQMGB) anneals to the ―C‖ form 
(―G‖ on the opposite strand, TaqIA-2, containing the restriction site, 178 bp restriction 
fragment).  Cycling parameters used were a 10 min hold at 95ºC followed by 40 cycles of 
92ºC for 15 sec and 60ºC for 60 sec.  Each 96 well plate included six non-template 
controls, four samples homozygous for the A SNP, four samples homozygous for the G 
SNP and two heterozygous samples.  Genotypes were scored independently by two 
individuals.  
 
CYP2A6*2 SNP (dbSNP reference: rs1801272; LocusID: 1548).  The CYP2A6 gene 
maps to 19q12-13.2, and has been found to contain several genomic alterations that 
include synonymous and nonsynonmous nucleotide changes and genetic deletions 
[27,28].  One nonsynonymous change is a T→A nucleotide substitution at codon 60 in 
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exon 3, that results in a substitution of leucine for histidine.  This produces a catalytically 
inactive protein product [29] that has been associated in epidemiological studies with 
reducing the number of cigarettes smoked [30,31,32].  The CYP2A6*2 assay [25] was 
performed using the fluorogenic 5’nuclease  (Taqman , Applied Biosystems, Foster 
City, CA) method using reagents (VIC  and FAM  labeled probes and TaqMan® 
Universal PCR Master Mix without AMPerase  UNG) obtained from Applied 
Biosystems (ABI).  Unlabeled forward and reverse primers were purchased from ABI or 
Integrated DNA Technologies (Coralville, IA).  All reactions were performed in an ABI 
Prism  7000 Sequence Detection System using the allelic discrimination mode as 
described by Livak [26] and in the accompanying instrument documentation.  Methods 
used were as described in the package inserts from ABI, except that the total reaction 
volume was decreased to 20 µl.  Reactions contained 1 µl of DNA (approximately 20 ng 
of DNA), 8.5 µl of water, 0.5 µl of 40x primer/probe mix and 10 µl of 2x Taqman  
Universal Master Mix.  Primer and probe sequences were obtained from the 
SNP500Cancer Database (//snp500cancer.nci.nih.gov).  Final primer and probe 
concentrations were 900 mM and 200 mM, respectively.  The sequences of primers and 
probes were: Forward Primer: 5’-AGGAGGCGGGCTTCCT-3’; Reverse Primer:  5’-
TCGTCCTGGGTGTTTTCCT-3’; Probe 1: 5’- FAM-TCGACGCCCTCCGGGGC-
TAMRA-3’; Probe 2: 5’- VIC-TCGACGCCCACCGGGGC-TAMRA-3’. Probe 1 
(FAM/TAMRA) anneals to the A-containing SNP (histidine-containing, inactive 
enzyme) and probe 2 (VIC/TAMRA) anneals to the T-containing SNP (leucine-
containing, active enzyme).  Cycling parameters used were a 10 min hold at 95ºC 
followed by 40 cycles of 92ºC for 15 sec and 60ºC for 60 sec.  Each 96 well plate 
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included six non-template controls, four samples homozygous for the A SNP, four 
samples homozygous for the T SNP and two heterozygous samples.  Genotypes were 
scored independently by two individuals.  
 
Amplification of target sequences by Polymerase Chain Reaction.  PCR reactions 
contained 1 µl of genomic DNA (20 ng or less), 10% dimethylsulfoxide (DMSO, Hybra-
Max® grade, Sigma, St Louis, MO), 1.8 mM MgClB2B, 180 µM deoxynucleotides, with 7'-
deaza-2'-deoxyGTP (Roche Applied Science, Indianapolis, IN) substituted for one-half of 
the dGTP, forward and reverse primers (DRD4, 480 nM, DAT1, 400 nM, 5HTT, 600 
nM, obtained from IDT, Coralville, IA) and 1 unit of AmpliTaq Gold® polymerase (PE-
Biosystems, Foster City, CA), and 1x PCR II buffer (PE-Biosystems) in a total volume of 
20 µl.  Amplification was performed using touchdown PCR [13].  A 95 P
o
PC incubation for 
10 min was followed by two cycles of 95 P
o
PC for 30 sec, 65 P
o
PC for 30 sec, and 72 P
o
PC for 
60 sec.  The annealing temperature was decreased every two cycles from 65 P
o
PC to 57 P
o
PC 
in 2P
o
PC increments (10 cycles total), and a final thirty cycles of 95 P
o
PC for 30 sec, 65 P
o
PC 
for 30 sec, and 72 P
o
PC for 60 sec and a final 30 min incubation at 72 P
o
PC.  
 
After amplification, 1 µl of PCR product was combined with 2 µL of loading buffer 
containing size standard (Genescan 2500 TAMRA®, PE-Biosystems), and 0.8 µl was 
loaded into each of 48 lanes of a 12-cm gel. PCR products were electrophoresed through 
a 4.25% polyacrylamide gel under denaturing conditions (6M urea) with Perkin Elmer 
ABI Prism 377 DNA sequencer using protocols supplied by the company.  Allele sizes 
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were scored by two investigators independently, and inconsistencies were reviewed and 
rerun if necessary.  
 
We have tested the validity of allele calls for the three genotyping protocols described 
above, using preamplified DNA compared with genomic DNA for 315 individuals (1890 
allele calls) from non-AddHealth samples.  Allele calls agreed in 98.7% of cases between 
the two methods, with essentially equivalent, and low, rates of missing genotypes, 
incorrect calls, and unresolved inconsistencies [14]. 
 
Determination of Zygosity.  Zygosity of twin subjects in the sample will be determined 
by genotyping 11 highly informative microsatellite markers, which we have been using 
for the last six years.  The PCR conditions will include 200 µM of each of the four 
dNTP's, 2.5 mM MgClB2B, 200 nM forward primer (fluorescently labeled), 200 nM reverse 
primer, approximately 20 ng of genomic DNA, 1 unit of AmpliTaq Gold polymerase and 
1x PCR II buffer in a total volume of 20 µl. Microsattelite loci used for zygosity 
determination are: D1S1679, D2S1384, D3S1766, D4S1627, D6S1277, D7S1808, 
D8S1119, D9S301, D10S1208, D13S796, D15S652 and D20S481.  Three multiplexed 
PCR reactions containing four primer pairs each will be run for each individual.  Tubes 
are capped and placed in a Perkin Elmer 9600 thermocycler.  The amplification is run 
with the following conditions: 95P
o
PC for 10 min (to activate the Gold polymerase); 35 
cycles of 94P
o
PC for 10 sec, 55P
o
PC for 90 sec, and 72P
o
PC for 90 sec; a final elongation at 
72P
o
PC for 8 min; and a hold at 4P
o
PC when finished.  PCR products are stored at -20P
o
PC until 
analyzed.  Electrophoresis will be performed as described above.  To control for potential 
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genotyping errors, any analysis that is questionable is repeated.  This includes poor 
amplification (small peaks), potential problems with gel quality, size standards or 
software problems such as lane tracking or analysis programs (Genscan or Genotyper), 
all of which are routine. 
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